Lipid conjugates in the treatment of chronic rfhinosinusitis

Abstract

This invention provides a method of treating, suppressing, inhibiting, or preventing chronic rhinosinusitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a method of treating, suppressing, inhibiting, or preventing nasal polyps in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.

What is claimed is: 
     
         1 . A method of treating or preventing chronic rhinosinusitis in a subject, comprising the step of administering to said subject a compound represented by the structure of the general formula (A):
   [L-Z—Y□ n X  n (A)
   wherein   L is a lipid or a phospholipid;   Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;   Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;   X is a polymer; and   
       n is a number from 1 to 1000. 
     
     
         2 . The method according to  claim 1 , wherein X is a polysaccharide. 
     
     
         3 . The method according to  claim 1 , wherein L is phosphatidylethanolamine. 
     
     
         4 . The method according to  claim 3 , wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine. 
     
     
         5 . The method according to  claim 1 , wherein said chronic rhinosinusitis is chronic rhinosinusitis with polyps. 
     
     
         6 . The method according to  claim 1 , wherein L is a phospholipid, Z is nothing and-said compound is represented by the structure of the general formula (I): 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; 
         R 2  is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; 
         Y is either nothing or a spacer group ranging in length from 2 to 30 atoms; 
         X is a polymer; and 
         n is a number from 1 to 1,000. 
       
     
     
         7 . The method of  claim 1 , wherein said polymer has a molecular weight of between 5 kD and 90 kD. 
     
     
         8 . The method of  claim 1 , wherein said polymer has a molecular weight of between 5 kD and 20 kD. 
     
     
         9 . The method of  claim 1 , wherein n is a number from 2 to 500. 
     
     
         10 . The method of  claim 1 , wherein the step of administering comprises nasal administration. 
     
     
         11 . A method of treating or preventing nasal polyps in a subject, comprising the step of administering to said subject a compound represented by the structure of the general formula (A):
   [L-Z—Y□ n X  (A)
   wherein   L is a lipid or a phospholipid;   Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;   Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;   X is a polymer; and   n is a number from 1 to 1000.   
     
     
         12 . The method according to  claim 11 , wherein X is a polysaccharide. 
     
     
         13 . The method according to  claim 11 , wherein L is a phosphatidylethanolamine. 
     
     
         14 . The method according to  claim 13 , wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine. 
     
     
         15 . The method according to  claim 11 , wherein L is a phospholipid, Z is nothing and said compound is represented by the structure of the general formula (I): 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; 
         R 2  is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; 
         Y is either nothing or a spacer group ranging in length from 2 to 30 atoms; 
         X is a polymer; and 
         n is a number from 1 to 1,000. 
       
     
     
         16 . The method of  claim 11 , wherein said polymer has a molecular weight of between 5 kD and 90 kD 
     
     
         17 . The method of  claim 11 , wherein said polymer has a molecular weight of between 5 kD and 20 kD. 
     
     
         18 . The method of  claim 11 , wherein n is a number from 2 to 500. 
     
     
         19 . The method of  claim 11 , wherein the step of administering comprises nasal administration.